Soleno Therapeutics Files 8-K
Ticker: SLNO · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, Regulation FD
TL;DR
SOLENO filed an 8-K today - likely a Reg FD disclosure, check for updates.
AI Summary
On September 10, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material information that may be of interest to investors. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Soleno Therapeutics has made a disclosure under Regulation FD, which could contain important information for investors regarding company events or communications.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for a Regulation FD disclosure, with no immediate indication of significant negative or positive events.
Key Players & Entities
- SOLENO THERAPEUTICS INC (company) — Registrant
- September 10, 2025 (date) — Date of Report
- Regulation FD (regulation) — Disclosure Type
- Delaware (jurisdiction) — State of Incorporation
- 100 Marine Parkway, Suite 400 Redwood City, CA 94065 (address) — Principal Executive Offices
FAQ
What specific information is being disclosed under Regulation FD?
The provided excerpt does not specify the content of the Regulation FD disclosure; it only indicates that such a disclosure has been made.
When was this 8-K filing submitted?
The filing was submitted on September 10, 2025.
What is the primary business of Soleno Therapeutics, Inc.?
Soleno Therapeutics, Inc. is in the business of Pharmaceutical Preparations, as indicated by its SIC code [2834].
What was the former name of Soleno Therapeutics, Inc.?
The former name of Soleno Therapeutics, Inc. was Capnia, Inc., with a date of name change on February 19, 2010.
Where are Soleno Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
Filing Stats: 752 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2025-09-10 12:34:45
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d88981d8k.htm (8-K) — 24KB
- 0001193125-25-199882.txt ( ) — 135KB
- slno-20250910.xsd (EX-101.SCH) — 3KB
- slno-20250910_lab.xml (EX-101.LAB) — 18KB
- slno-20250910_pre.xml (EX-101.PRE) — 11KB
- d88981d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: September 10, 2025 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer